Termes de recherche populaires :
Résultats de la recherche
6 résultats trouvés-
Des pourcentages comparables d'EIG ont été signalés chez les sujets des groupes FLUCELVAXMD QUAD, VAT1c et VAT2c (3,9 %, 3,3 % et 3,2 % respectivement).
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-fr/flucelvax-quad_fr-clean-pm_asu-2024-2025_watermark.pdf -
Immunization should be carried out on separate limbs.
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/fluad_en-clean-pm_asu-2024-2025_watermark.pdf -
4.4 Administration Vaccination should be carried out by intramuscular injection, preferably into the deltoid muscle of the upper arm.
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/afluria-tetra_en-clean-pm_asu-2024-2025_watermark.pdf -
d) Customer goes into involuntary liquidation or otherwise ceases or threatens to cease to carry on business or takes or suffers any similar action in consequence of debt
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/seqirus-canada-inc-2024-terms--conditions-final-april-25-en-cancrp240009.pdf -
Les taux d'effets indésirables qui y sont observés ne reflètent pas nécessairement les taux observés en pratique, et ces taux ne doivent 1 Osterman MJK, Hamilton BE, Martin JA, Driscoll AK, et al.
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-fr/afluria-tetra_fr_clean_pm_asu-2024-2025_watermark.pdf -
4.4 Administration Vaccination should be carried out by intramuscular injection, preferably into the deltoid muscle of the upper arm.
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/afluria-product-monograph---asu-2022-23---en-final-approved-12-may-2022.pdf